Efficacy and safety of darolutamide plus androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial
NCODA Oncology and Hematology Meeting Abstracts · 07.04.2026
DOI: 10.67209/tfdj1461 ↗Kurz gefasst
Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, online erschienen am 07.04.2026. Verfasst von Kirollos Hanna und 18 weiteren Autor:innen. Die Arbeit nennt 2 Literaturangaben.
Abstract (Originalsprache)
In ARASENS, darolutamide + androgendeprivation (ADT) + docetaxel significantly improved overall survival vs ADT + docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC), and incidences of treatment-emergent adverse events (TEAEs) were similar in both groups. The phase 3 global ARANOTE trial2 (NCT04736199) compared darolutamide + ADT versus (vs) ADT in patients with mHSPC. The primary results are reported. Eligible patients had mHSPC by conventional imaging, Eastern Cooperative Oncology Group (ECOG) performance status of 0–2, and started ADT ≤12 weeks. Patients were randomized 2:1 to darolutamide 600 mg twice daily or placebo, each with ADT. The primary endpoint was radiological progression-free survival (rPFS). Secondary endpoints included overall survival, time to initiation of subsequent anticancer therapy, time to castration-resistant prostate cancer (CRPC), time to prostate-specific antigen (PSA) progression, time to pain progression, and safety.
Zitieren
APA
Hanna, K., Saad, F., Vjaters, E., Shore, N., Olmos, D., Xing, N., Gomes, A. J. P. D. S., Mota, A. C. D. A., Salman, P., Jievaltas, M., Jakubovskis, M., Ulys, A., Kopyltsov, E., Han, W., Testa, I., Berre, M. A. L., Kuss, I., Nevalaita, L., & Haresh, K. P. (2026). Efficacy and safety of darolutamide plus androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial. NCODA Oncology and Hematology Meeting Abstracts. https://doi.org/10.67209/tfdj1461
Vancouver
Hanna K, Saad F, Vjaters E, Shore N, Olmos D, Xing N, et al. Efficacy and safety of darolutamide plus androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial. NCODA Oncology and Hematology Meeting Abstracts. 2026. doi:10.67209/tfdj1461
BibTeX
@article{Hanna2026,
author = {Hanna, Kirollos and Saad, Fred and Vjaters, Egils and Shore, Neal and Olmos, David and Xing, Nianzeng and Gomes, Andrea Juliana P. de Santana and Mota, Augusto Cesar de Andrade and Salman, Pamela and Jievaltas, Mindaugas and Jakubovskis, Maris and Ulys, Albertas and Kopyltsov, Evgeny and Han, Weiqing and Testa, Isabella and Berre, Marie Aude Le and Kuss, Iris and Nevalaita, Liina and Haresh, Kunhi Parambath},
title = {Efficacy and safety of darolutamide plus androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial},
journal = {NCODA Oncology and Hematology Meeting Abstracts},
year = {2026},
doi = {10.67209/tfdj1461}
}
EUVIMED